TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05635201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia induction with propofol
Description: After a 10-minute-long acclimation, general anesthesia is induced with 2% propofol at the effect-site concentration of 4 μg/ml based on the Marsh Pharmacokinetic model. The effect-site concentration was maintained at 4 μg/ml until the trachea was intubated. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentrations of propofol and remifentanil were decreased to 3 μg/ml and 0 ng/ml, respectively, until the surgical incision was made.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction with remimazolam
Description: After a 10-minute-long acclimation, general anesthesia is induced with a 2-minute-long infusion of remimazolam at a rate of 12 mg/kg/hr, after which the infusion rate was reduced to 1 mg/kg/hr and was maintained until the surgical incision was made. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentration of remifentanil was decreased to 0 ng/ml until the surgical incision was made.
Study: NCT05944952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: Participants will be dosed with buprenorphine/ naloxone strips

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine/naloxone
Description: Participants will be dosed with buprenorphine/ naloxone strips
Study: NCT05777655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication management app (mediteo m+, Mediteo GmbH, Heidelberg)
Description: Free access to a study version of the medication management app mediteo m+ for reminders and documentation of statin therapy in addition to usual care
Study: NCT05906368

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ClearSight HPI Monitoring system
Description: Continuous blood pressure monitoring for precision hypotensive event response

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard of Care Blood Pressure Monitoring
Description: Blood pressure (BP) monitoring using a conventional arm cuff and inflation after epidural anesthesia as standard procedure. Standard of care blood pressure monitoring includes measurement of blood pressure at the time of epidural test dose delivery, 3-minute cycles of BP monitoring for 30 minutes after epidural placement, and then BP monitoring every 15 minutes per existing clinical standards for at least 4-hours, or until delivery.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Standard of Care Blood Pressure Monitoring
Description: Blood pressure (BP) monitoring using a conventional arm cuff and inflation after epidural anesthesia as standard procedure. Standard of care blood pressure monitoring includes measurement of blood pressure at the time of epidural test dose delivery, 3-minute cycles of BP monitoring for 30 minutes after epidural placement, and then BP monitoring every 15 minutes per existing clinical standards for at least 4-hours, or until delivery.
Study: NCT05397418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise program
Description: 12 week supervised low impact resistance training program

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Unsupervised resistance exercise program
Description: 12 week unsupervised low impact resistance training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised resistance exercise program
Description: 12 week unsupervised low impact resistance training program
Study: NCT05968105

Intervention type: PROCEDURE
Intervention: Lateral Sagittal Infraclavicular Block
Description: Patients will be in the supine position and after aseptic conditions are provided, the axillary artery of the patient will be visualized in the craniocaudal plane, in the infraclavicular region and in the lateral sagittal position with the help of an 8-12 mHz linear probe. After the brachial plexus cords around the axillary artery are identified, a local anesthetic mixture will be applied in-plane between the posterior cord and the artery. During the block, patients will routinely be given a mixture of 0.25% bupivacaine + 0.5% lidocaine 0.5 mL/kg.

Intervention type: PROCEDURE
Intervention: Lateral Sagittal Infraclavicular Block
Description: Patients will be in the supine position and after aseptic conditions are provided, the axillary artery of the patient will be visualized in the craniocaudal plane, in the infraclavicular region and in the lateral sagittal position with the help of an 8-12 mHz linear probe. After the brachial plexus cords around the axillary artery are identified, a local anesthetic mixture will be applied in-plane between the posterior cord and the artery. During the block, patients will routinely be given a mixture of 0.25% bupivacaine + 0.5% lidocaine 0.5 mL/kg.

Intervention type: PROCEDURE
Intervention: Inferior vena cava diameter >1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) < 50%
Description: While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.

Intervention type: DIAGNOSTIC_TEST
Intervention: Inferior vena cava diameter <1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) > 50%
Description: While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
Study: NCT05264116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS
Description: Reprocessed noninvasive pulse oximeter sensors.
Study: NCT05069467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: For the active acupuncture group, the acupuncturist chose standard points depending on subjects' preferred positions. In addition, up to four acupuncture points were chosen on the basis of subjects' other presenting symptoms (such as fatigue, insomnia, or erectile dysfunction). The needles (30 or 40 mm and 0.25 mm gauge; Soochow, Hwato) will be inserted and manipulated until De Qi, a sensation of soreness and tingling.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Treatment will be the same for the sham acupuncture, except for the following: the acupuncturist selected the same number of nonacupuncture, nontrigger points. Instead of eliciting De Qi, the needles will be minimally manipulated to avoid eliciting sensations other than initial contact with skin.
Study: NCT06013566

Intervention type: DEVICE
Intervention: SSVEP
Description: Non-invasive, non-interventional SSVEP EEG device

Intervention type: DEVICE
Intervention: SSVEP
Description: Non-invasive, non-interventional SSVEP EEG device

Intervention type: DEVICE
Intervention: SSVEP
Description: Non-invasive, non-interventional SSVEP EEG device
Study: NCT05115396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The patient shall be seated in a chair with a table in front of him/her. On the table there is a mirror in the sagittal plane between the two upper extremities. The affected hand will be behind the mirror, without visibility, while the hand without symptoms will be reflected laterally in the mirror. Thus, the mirror will reflect the movements of the unaffected side as if these movements were executed with the affected side. During the procedure, patients will be instructed to concentrate on the hand reflected in the mirror.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-education treatment
Description: Participants will perform the same exercise protocol with the unaffected hand and without the use of a mirror.
Study: NCT05662813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib 110mg p.o qd. Patients receive Almonertinib treatment until disease progression, unacceptable toxicity or other discontinuation criteria.
Study: NCT05192642

Intervention type: DRUG
Intervention: Larotrectinib(Vitrakvi, BAY2757556)
Description: Clinical trials

Intervention type: DRUG
Intervention: Data on other treatments
Description: Real word data
Study: NCT05278897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Tissue Adapted Biocompatible Hyaluronic Acid
Description: 1% sodium hyaluronate
Study: NCT05244200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care and insulin staging.
Description: Pharmaceutical care is a patient-centered practice in which the practitioner assumes responsibility for a patient's drug-related needs and is held accountable for this commitment. Due to the progressive nature of Type 2 Diabetes Mellitus, which requires timely optimization of treatment, leading in a majority of cases to insulin therapy, so that proper use of insulin is one of the critical tools for prevention of long-term complications. From the hundred patients in this study, half of the patients will be the control group without any intervention, and pharmaceutical care and insulin staging will be applied on the remaining. In this research two strategies will be applied including pharmaceutical care process and Insulin Staging approach on patients with T2DM, those who are on end stage treatment.
Study: NCT05188105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha tACS (12 Hz) over the occipital cortex
Description: Single session of alpha tACS (12 Hz) over the occipital cortex

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Alpha tACS (12 Hz) over the occipital cortex
Description: Single session of alpha tACS (12 Hz) over the occipital cortex
Study: NCT05724290

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EGR2
Description: We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EGR2
Description: We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.
Study: NCT05937880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: When patients appeared with rashes and treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. The rashes do not subside or fresh rash still appears, and it frequently repeats more than 3 times during hospitalization. Leflunomide would be administered
Study: NCT05053581

Intervention type: OTHER
Intervention: Survey
Description: Patients will complete 7 questionnaires at inclusion (T0) and 1,3 and 6 months after start of CPAP treatment
Study: NCT03555552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anticoagulation and Thrombosis Point of Care Test(AT-POCT)
Description: Capillary action automatically draws blood into the channel containing printed assay reagents which solubilize upon contact with blood and react with analytes of interest.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation and Thrombosis Point of Care Test(AT-POCT)
Description: Capillary action automatically draws blood into the channel containing printed assay reagents which solubilize upon contact with blood and react with analytes of interest.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duke Central Automated Laboratory (DCAL)
Description: DCAL measurement of INR will occur by an ACL TOP 750 Analyzer (IL Inc.), and LDH by standard enzymatic activity assay will be run on the automated Beckman DxC800.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duke Central Automated Laboratory (DCAL)
Description: DCAL measurement of INR will occur by an ACL TOP 750 Analyzer (IL Inc.), and LDH by standard enzymatic activity assay will be run on the automated Beckman DxC800.
Study: NCT06351176

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical tests
Description: The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical tests
Description: The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical tests
Description: The investigators perform blood and urine tests in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical tests
Description: The investigators perform blood and urine tests in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: DXA scan with TBS and VFA
Description: The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) including trabecular bone score (TBS) and Vertebral Fracture Assessment (VFA) in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: DXA scan with TBS and VFA
Description: The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) including trabecular bone score (TBS) and Vertebral Fracture Assessment (VFA) in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: AGEReader
Description: The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.

Intervention type: DIAGNOSTIC_TEST
Intervention: AGEReader
Description: The investigators perform a skin advanced glycation end products (AGEs) measurement with the AGE Reader machine in every participant.
Study: NCT06551740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344
Description: per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344
Description: per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344-R1, HUC2-344-R2
Description: per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344-R1, HUC2-344-R2
Description: per oral
Study: NCT04772443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1506
Description: DWJ1506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1507
Description: DWJ1507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWC202011
Description: DWC202011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWJ1177
Description: DWC202011
Study: NCT05893238

Intervention type: PROCEDURE
Intervention: Natural cycle In Vitro Fertilisation (IVF)
Description: In Vitro Fertilisation (IVF) without hormonal stimulation

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for analysis
Description: Test hormone levels in serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for analysis
Description: Test hormone levels in serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Follicular fluid for analysis
Description: Test hormone levels in follicular fluid Test Oxidation-reduction potential

Intervention type: DIAGNOSTIC_TEST
Intervention: Follicular fluid for analysis
Description: Test hormone levels in follicular fluid Test Oxidation-reduction potential

Intervention type: DIAGNOSTIC_TEST
Intervention: Sperm samples for analysis
Description: Oxidation-reduction potential

Intervention type: DIAGNOSTIC_TEST
Intervention: Sperm samples for analysis
Description: Oxidation-reduction potential

Intervention type: PROCEDURE
Intervention: Conventional In Vitro Fertilisation (IVF)
Description: In Vitro Fertilisation (IVF) with conventional hormonal stimulation
Study: NCT05277207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Smoking Cessation Facilitation Meetings
Description: Participants will participate in 5-7 meetings in which they will receive cognitive-behavioral therapy for tobacco cessation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalized Smoking Cessation Pharmacotherapy
Description: Participants may receive pharmacotherapy for smoking cessation based on VA Pharmacy Benefits Management Services guidelines. Medications may include nicotine-replacement therapy, varenicline, and/or bupropion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Text Messaging Support
Description: If the participant has a working cell phone and is willing to receive text messages, supportive, personalized text messages will be sent to the participant starting after Session 1 and extending through 6 months post-quit using VA's Annie texting capability.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SmokefreeVET
Description: Participants will receive a referral to SmokefreeVET, a text-messaging intervention designed to help veterans prepare for and attempt quitting smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Quitline
Description: Participants will receive a referral to VA Quitline, which is a nationally available telehealth intervention that provides assistance to veterans who wish to quit tobacco use. Quitline includes five sessions of cognitive-behavioral treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education about pharmacotherapy
Description: Participants will receive a handout that provides them with information about pharmacotherapies for tobacco cessation.
Study: NCT04900311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib + trastuzumab + nab-paclitaxel
Description: patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pyrotinib: 400 mg/day, orally, qd trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pertuzumab + trastuzumab + nab-paclitaxel
Description: patients will be treated every 3 weeks for four cycles prior to surgery at following doses: pertuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 840 mg for Cycle 1, followed by 420 mg for Cycles 2-4 trastuzumab: IV infusion on Day 1 every 3 weeks with loading dose of 8 mg/kg in Cycle 1, and 6 mg/kg in Cycles 2-4 nab-paclitaxel: 260 mg/m2 IV infusion on Day 1 every 3 weeks, or 125 mg/m2 IV infusion on Days 1, 8 and 15 every 3 weeks (the nab-paclitaxel administration cycle was determined by investigator at each site)
Study: NCT05342571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Participate in ABC session

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Medical records reviewed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive patient guidebook

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete surveys
Study: NCT06269783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sipIT
Description: Automated and manual fluid tracking system with just-in-time reminder messages to support fluid intake habit formation.
Study: NCT05412134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro2 - 75% of participant's MIP
Description: Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback.~Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pro2 - 15% of participant's MIP
Description: Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition. Participants will perform 3 sets of 50 inspiratory breaths 3 times per week.
Study: NCT06170710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Postoperative CCRT followed by any anti-PD-1 monoclonal antibody of the following:~Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative CCRT
Description: Postoperative chemoradiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative CCRT
Description: Postoperative chemoradiotherapy
Study: NCT02502370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: observation alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV5FU2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX